Differential effects of bariatric surgery on plasma levels of ANGPTL3 and ANGPTL4

Bini, Simone; D’Erasmo, Laura; Astiarraga, Brenno; Minicocci, Ilenia; Palumbo, Maria Giovanna; Pecce, Valeria; Polito, Luca; Costanzo, Alessia Di; Haeusler, Rebecca A.; Arca, Marcello; Ferrannini, Ele; Camastra, Stefania

doi:10.1016/j.numecd.2022.08.019

Cited by 3 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hepatokine ANGPTL3 did not differ between surgery and comparator-subjects-with-obesity or normal-weight subjects; ANGPTL3 levels have been shown to differ post bariatric surgery depending on the type of surgery undertaken though, in accord with the results here, they were reported not to change following Rouxen-Y surgery (31), suggesting that differing bariatric surgery procedures have differing metabolic impacts.…”

Section: Discussionsupporting

confidence: 78%

“…Similarly, the ANGPTL4 hepatokine levels were significantly lower in normal-weight subjects compared to surgery patients, whilst they did not differ between surgery and comparator-subjects-with-obesity. ANGPTL4 is recognized to fall following Roux-en-Y surgery ( 31 , 32 ); however, that fall was not compared to a normal population and therefore a novel finding of this study is that the fall reported here is not to the level found in subjects with a normal BMI. This again suggests that restoration of the homeostatic parameters may only occur with weight loss to below a BMI of 34 kg/m 2 or perhaps even to a normal BMI.…”

Section: Discussionmentioning

confidence: 62%

“…Given the many adipokines, hepatokines and myokines, this study focused on those adipokines (25,26), hepatokines (27)(28)(29)(30)(31)(32) and the myokine, myonectin (24), that have been previously reported to be altered in response to bariatric surgery, weight loss, lipid regulation and glucose homeostasis. A schematic illustration of the sources of hepatokines, adipokines and myokines, and their roles in lipid metabolism and energy homeostasis, is shown in Figure 1.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical improvement may not reflect metabolic homeostasis normalization in subjects with and without Roux-En-Y bariatric surgery after 12 years: comparison of surgical subjects to a lean cohort

Butler,

Ramanjaneya,

Moin

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundA 12-year study comparing clinical outcomes following Roux-en-Y bariatric surgery showed long-term weight loss with remission/prevention of type-2-diabetes (T2D), hypertension and dyslipidemia. However, it is unknown whether the underlying homeostatic metabolic processes involving hepatokines, adipokines and myokines also normalize. Using this 12-year study, we determined whether metabolic indices improved in post-surgical (BMI:34.4kg/m2) versus non-surgical comparator-subjects-with-obesity (BMI:43.8kg/m2) at 12-year follow-up (both cohorts with baseline diabetes), and if post-surgical subjects normalized their metabolic processes to those of a normal-weight cohort without diabetes.MethodsCross-sectional design. Plasma from a cohort of Roux-en-Y bariatric surgery (n=50) and non-surgery (n=76) comparator-subjects-with-obesity (both cohorts at 12-year follow-up) plus a normal-weight cohort (n=39) was assayed by Luminex immunoassay or ELISA for hepatokines [angiopoietin-like proteins-(ANGPTL3; ANGPTL4; ANGPTL6); fibroblast growth factors-(FGF19; FGF21; FGF23)]; adipokines [adipsin; adiponectin; FGF19] and myonectin.ResultsAfter age and gender adjustment, surgery versus comparator-subjects-with-obesity had lower BMI (34.4 ± 1.0 vs 43.8 ± 0.9kg/m2; p<0.0001), HbA1c (6.2 ± 0.3 vs 7.7 ± 0.2%; p<0.0001), insulin resistance (HOMA-IR, 2.0 ± 1.5 vs 10.8 ± 1.4; p<0.0001) fat mass (45.6 ± 2.2 vs 60.0 ± 2.0; p<0.0001), HDL-C (55.4 ± 2.6 vs 42.6 ± 2.3mg/dL; p<0.0001), triglycerides (130 ± 14 vs 187 ± 12mg/dL; p<0.0001) and higher adiponectin (25.9 ± 2.3 vs 15.7 ± 2.0µg/ml; p<0.001); Adipsin, ANGPTL3, ANGPTL4, ANGPTL6, FGF19, FGF21, FGF23 and myonectin did not differ. Surgery versus normal-weight group: higher ANGPTL4 (156 ± 6 vs 119 ± 7ng/mL; p<0.0001), higher FGF23 (96.4 ± 10.1 vs 50.9 ± 11.5pg/mL; p=0.007) and lower myonectin (744 ± 55 vs 969 ± 66ng/mL; p=0.002); adiponectin, adipsin ANGPTL3, ANGPTL6, FGF19, FGF21 did not differ. Non-surgery comparator-subjects-with-obesity versus normal-weight group: higher adipsin (1859 ± 94 vs 1314 ± 133ng/mL; p=0.0001), higher FGF23 (84.6 ± 8.5 vs 50.9 ± 11.5pg/mL; p<0.0001) and higher ANGPTL4 (171 ± 5 vs 119 ± 7ng/mL; p<0.0001); adiponectin ANGPTL3, ANGPTL6, FGF19, FGF21 and myonectin did not differ.ConclusionBariatric surgery markedly improved anthropometric and metabolic features versus comparator-subjects-with-obesity at 12-year follow-up, indicating benefit of weight loss. However, despite weight loss, these patients still had class-1 obesity, as reflected in the adipokine, hepatokine and myokine markers of body homeostasis that did not completely normalize to indicative values of normal-weight subjects, suggesting either that this is the new normal for these patients or that weight loss to a BMI<25kg/m2 is needed for normalization of these parameters.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical improvement may not reflect metabolic homeostasis normalization in subjects with and without Roux-En-Y bariatric surgery after 12 years: comparison of surgical subjects to a lean cohort

Butler,

Ramanjaneya,

Moin

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Thus, the change in ANGPTL6 levels can be associated with the process of weight loss, regardless of the cause for nutritional deficiency. In a 2022 study, plasma ANGPTL3 and ANGPTL4 concentration levels were shown to change after surgery: ANGPTL4 decreases after surgery, while ANGPTL3 concentration increases, but only after BPD (Bini et. al., 2022).…”

Section: Discussionmentioning

confidence: 99%

Circulating biomarker profile changes in obese patients undergoing bariatric surgery

Sushentseva,

Apalko,

Popov

et al. 2024

BioComm

View full text Add to dashboard Cite

Bariatric surgery (BS) remains the most effective treatment for morbid obesity (MO). It`s relevant to identify biomarkers for predicting the outcome of BS in patients with MO. The aim of the study was to determine the dynamical change in the biomarker levels in patients undergoing BS and apparently healthy donors. Serum and plasma samples were obtained from 66 patients, of which 26 patients with MO (aged 26–72 years) underwent BS, and 40 healthy donors, at the age of 56 ± 10.3 years. Patient samples were obtained the day before BS (first group), 3–7 months after BS (second group), and 7 or more months after BS (third group). Analyte concentrations were determined by multiplex immunoassay on the xMAP platform (Luminex). Spearman’s rank correlation was used. The nature of analyte variability was described by building multiple regression models. In the patients compared with healthy controls, differences in the levels of resistin, PAI1, MCP1, GLP1, leptin, FGF23, adiponectin, adipsin were observed. In patients after BS, the levels of resistin, ANGPTL6, FGF21, and leptin changed. In patients over 55 years old compared with younger patients, differences for total ANGPTL4, amylin, and pancreatic polypeptide were observed. Differences in levels of glucagon, resistin, GLP1 and leptin were noted between men and women. The dynamics of the levels of adipokines and incretins indicates biochemical changes in patients after BS compared with healthy persons.

show abstract

Unveiling the Hub Genes Associated with Aflatoxin B1-Induced Hepatotoxicity in Chicken

Yang

2023

Preprint

View full text Add to dashboard Cite

Differential effects of bariatric surgery on plasma levels of ANGPTL3 and ANGPTL4

Cited by 3 publications

References 42 publications

Clinical improvement may not reflect metabolic homeostasis normalization in subjects with and without Roux-En-Y bariatric surgery after 12 years: comparison of surgical subjects to a lean cohort

Clinical improvement may not reflect metabolic homeostasis normalization in subjects with and without Roux-En-Y bariatric surgery after 12 years: comparison of surgical subjects to a lean cohort

Circulating biomarker profile changes in obese patients undergoing bariatric surgery

Unveiling the Hub Genes Associated with Aflatoxin B1-Induced Hepatotoxicity in Chicken

Contact Info

Product

Resources

About